Merkel cell carcinoma research study
Part of Cancer, Infections clinical trials.
This study looks at how people with Merkel cell carcinoma, a rare skin cancer, take part in clinical trials. By joining, you help researchers understand how to make trials easier for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with Merkel cell carcinoma.
- You can use a computer, tablet, or smartphone to fill out online forms.
- You understand the study and agree to take part by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for cancer cells in your blood before and after surgery (and possibly radiation) to learn more about your cancer and how it responds to treatment. Participation involves giving blood samples, which may help doctors understand your disease better.
This trial is a French national database that collects information from people with certain rare skin cancers. It may help researchers better understand these cancers and improve future care, using real-world patient data.
This trial tests a new combination for people with advanced Merkel cell carcinoma (MCC), a rare skin cancer. It combines the immunotherapy drug pembrolizumab with standard chemotherapy (cisplatin or carboplatin plus etoposide). The goal is to see if this combination shrinks or controls the cancer better than chemotherapy alone.
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
This trial tests a new drug called CRD3874-SI for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.
Hear when a new Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.